Again, CBD’s ability to reduce pain thanks to its interaction with the endocannabinoid system’s receptors can help reduce breast tenderness discomfort during a woman’s menstrual cycle.
Flaxseed is not only a leader in the content of this hormone but also a beneficial product. It also helps to cleanse the body and relieve inflammation. Meanwhile, it is recommended to be consumed in a ground form.
CBD, or cannabidiol , is one of the leading organic compounds found in the Cannabis sativa plant. It is currently emerging as one of the most promising therapeutic agents in various conditions such as epilepsy, different anxiety disorders, migraines, cancer, and even Alzheimer’s disorder.
Promote healthy cholesterol levels
Estrogens are female hormones of beauty and youth that stimulate the production of collagen and hyaluronic acid. They help to maintain the bone matrix and skin’s health and beauty – density, tone, hydration, and skin protection from photoaging.
An early review by the WHO suggests that CBD oil use is generally safe and effective for certain conditions, but conclusive research into the efficacy and safety during pregnancy hasn’t been done. So far, it is just known that marijuana use is unrecommended. Even a small amount of THC (in some CBD products) can pass through the placenta and cause developmental problems. So if you are still not confident, talk to your doctor and remember that it is always better to stick to the mindset of “better to be safe than sorry”!
Vaginal dryness may come as a shock to many women, but it is actually quite common. When estrogen levels reach an absolute minimum, vaginal tissue produces less lubrication, which reduces elasticity and can even lead to painful sensations during intercourse. Lubricants are well known as a practical solution, but many women find the synthetic chemical odor unpleasant when applied to the body’s most intimate parts. On the other hand, CBD oil has a pleasant scent, enhances natural lubrication, and improves well-being. For vaginal dryness, CBD oil can be mixed with other natural oils to relieve and reduce dryness in the long term.
Mood swings are a common symptom of menopause that causes irritation and depression in women. Many studies prove CBD is an effective mood stabilizer. Anandamide, commonly named the “bliss molecule”, is responsible for feelings of happiness and motivation. CBD oil acts as an anandamide reuptake inhibitor , stopping the neurotransmitter from being reabsorbed. It increases the amount present in the brain, resulting in an improved and elevated mood.
Endocannabinoids on the other hand encourage the sparing and storage of energy, in part by reducing thyroid hormones (1) .
Aromatase inhibitors are used to reduce estrogen levels in cases of breast cancer and post menopause (6) .
Most changes in hormone synthesis and secretion start in the hypothalamus, when cannabinoid receptor 1 is activated. This starts a series of hormonal messages that trickle down to other glands, which then secrete their own hormones in response.
Since CBD also interacts with CB1, long term use could affect GH levels. We need more studies to assess whether there’s a positive or negative effect of CBD on GH levels.
CBD also encourages the breakdown of estrogen by speeding up cytochrome p450 enzymes that break it down (7) .
The CB1 receptors are in the presynaptic neurons on the axon terminals. The endocannabinoids themselves are synthesized and released on demand by the postsynaptic neurons. When the receptors are bonded with the ligand endocannabinoids, the release of additional neurotransmitters by the presynaptic cell is blocked, thereby allowing regulation of neurotransmission of incoming signals. FAAH, fatty acid amide hydrolase, is an enzyme which breakdowns anandamide and monoacylglycerol lipase breakdowns 2- AG, controlling quantities. FAAH is under the control of estradiol.
Marijuana is commonly used and its use by women is rising. Women have been found to be more susceptible to abuse of cannabinoids and the development of dependence, and experience more severe withdrawal symptoms and relapse more often than do men. As well, when women use cannabinoids, they are more impacted, with altered functioning on tasks. In adolescents, females are more likely to be adversely affected than are male adolescents by cannabinoids. Importantly, it is now accepted that estradiol is the hormone that impacts this important sexual dimorphic effect of cannabinoids.
In rats which were ovariectomized and then given estradiol, there was an increase in the production of anandamide, showing that estradiol has a direct impact on its production as well as regulating its degradation. In summary, though more complex than what will follow, as the two systems have multiple pathways of interconnectivity, it appears that estradiol modulates the receptor activity, the production, and the degradation of the endocannabinoids, both in the CNS and peripherally. In turn, the endocannabinoids downregulate the production of estradiol by decreasing the release of gonadotropins.
The endocannabinoid system and estrogens have both direct and indirect interactions. The endocannabinoid system impacts the release of estrogens through the central down-regulation of LH and GnRH. When THC is given, there is a decrease in serum LH, and the pulsatile nature of LH is decreased. When GnRH was given to female rats, the effects of THC were reversed. This is suggestive that as the pituitary gland remains sensitive to stimulation, the impact of cannabinoids is through its effects on central neurotransmission, suppressing LH release. The suppression of LH release by THC has been demonstrated in monkeys and rats. It is complex and variable by brain region and even by synapses, but changes to the function of estrogen do influence central endocannabinoid signaling. There is clearly a complex interrelationship between endocannabinoid activity and estradiol levels. It certainly appears that the use of an exogenous cannabinoid could adversely impact the hormonal cycling and fertility of females.
Brain endocannabinoids have been recognized as major modulators of affect, motivation, and emotions, and the emerging connection to estradiol, and the other sex hormones, is only recently emerging and must now be recognized for their great significance in the functioning of this critical body system. We live in a world of endocrine disruptors, including pharmaceuticals which in fact are endocrine disruptors themselves – such as metformin, oral contraceptives, “hormonal” IUDs and implantables – and we should additionally recognize the inevitable and universal impact of menopause on the endocannabinoid system and its impact on women’s emotional regulation.
It is know recognized that the endocannabinoid system contains two types of cannabinoid receptors: CB1 and CB2 receptors. The ligands for these receptors are anandamide and 2-arachidonoylglycerol (2-AG). The CB1 receptors are in the central nervous system and in some peripheral sites. Within the CNS, they are primarily located within the neurons of the cerebral cortex, hippocampus, amygdala, hypothalamus, basal ganglia, and cerebellum. The CB2 receptors are predominantly found in peripheral tissues and in cells of the immune system.
Endocannabinoid activity as well as CB1 receptor function fluctuates throughout the menstrual cycle. In humans, the amount of anandamide circulating is higher during the follicular phase and highest during ovulation, while being lower during the luteal phase. It appears that the endocannabinoid system is significant in the regulation of the menstrual cycle and indeed does play a role in fertility. Various components of the endocannabinoid system have been found in the ovaries and uterus, and levels vary in a set manner during the time of embryo implantation. Data suggests that low anandamide levels are a requirement for implantation and for carrying a pregnancy to term, while high levels of anandamide facilitates the labor process. In fact, it has been found that during pregnancy there are low levels of anandamide present and a surge occurs near the time of labor onset. As well, with increased levels of anandamide or if an agonist of it is given results in early pregnancy, a higher rate of miscarriages in humans is seen.